Authors : Tong M; Eye Institute and Department of Ophthalmology, Eye and ENT Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China.; Bai Y

Subjects: Angiogenesis* ; Neovascularization, Pathologic*; Humans

Source: Clinical and translational medicine [Clin Transl Med] 2024 Mar; Vol. 14 (3), pp. e1640.Publisher: Wiley Country of Publication: United States NLM ID: 101597971 Publication Model: Print Cited Medium: Internet

Record details

Read Online Read More Add to Saved list

Report

Engineering small-molecule analogues of altiratinib via CREB-regulated transcription co-activator 3-target screening for the development of potent and safe topical therapeutics against skin hyperpigmentary diseases.

Authors : Lee JH; Department of Dermatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.; An H

Subjects: Angiogenesis Inhibitors*

Source: Clinical and translational medicine [Clin Transl Med] 2024 Mar; Vol. 14 (3), pp. e1625.Publisher: Wiley Country of Publication: United States NLM ID: 101597971 Publication Model: Print Cited Medium: Internet

Record details

Read Online Read More Add to Saved list

Academic Journal

Bridging population pharmacokinetic and semimechanistic absorption modeling of APX3330.

Authors : Silva LL; Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indiana, Indianapolis, USA.; Stratford RE

Subjects: Hydroquinones* ; Neoplasms*; Humans

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Jan; Vol. 13 (1), pp. 106-117. Date of Electronic Publication: 2023 Oct 26.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium:

Record details

Read Online Read More Add to Saved list

Report

Pan-cancer landscape of tumour endothelial cells pinpoints insulin receptor as a novel antiangiogenic target and predicts immunotherapy response.

Authors : Zheng Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.; Pan YQ

Subjects: Endothelial Cells* ; Neoplasms*/Neoplasms*/Neoplasms*/drug therapy; Humans

Source: Clinical and translational medicine [Clin Transl Med] 2023 Dec; Vol. 13 (12), pp. e1501.Publisher: Wiley Country of Publication: United States NLM ID: 101597971 Publication Model: Print Cited Medium: Internet

Record details

Read Online Read More Add to Saved list

Academic Journal

Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2-positive advanced or metastatic breast cancer patients.

Authors : Tosca EM; Laboratory of Bioinformatics, Mathematical Modelling and Synthetic Biology, Department of Electrical, Computer and Biomedical Engineering, Università degli Studi di Pavia, Pavia, Italy.; Borella E

Subjects: Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/metabolism; Humans ; Animals

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Nov; Vol. 12 (11), pp. 1626-1639. Date of Electronic Publication: 2023 Feb 15.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium:

Record details

Read Online Read More Add to Saved list

Academic Journal

Emerging therapies and their delivery for treating age-related macular degeneration.

Authors : Thomas CN; School of Biomedical Sciences, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.; Sim DA

Subjects: Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/therapeutic use ; Wet Macular Degeneration*/Wet Macular Degeneration*/Wet Macular Degeneration*/chemically induced ; Wet Macular Degeneration*/Wet Macular Degeneration*/Wet Macular Degeneration*/drug therapy

Source: British journal of pharmacology [Br J Pharmacol] 2022 May; Vol. 179 (9), pp. 1908-1937. Date of Electronic Publication: 2021 May 12.Publisher: Wiley Country of Publication: England NLM ID: 7502536 Publication Model: Print-Electronic Cited Medium:

Record details

Read Online Read More Add to Saved list

Academic Journal

Advances in Engineered Biomaterials Targeting Angiogenesis and Cell Proliferation for Cancer Therapy.

Authors : Yadav P; Laboratory of Nanotechnology and Chemical Biology, Regional Centre for Biotechnology, NCR Biotech Science Cluster, 3rd Milestone Faridabad - Gurgaon Expressway, Faridabad, 121001, India.; Dua C

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Nanoparticles*

Source: Chemical record (New York, N.Y.) [Chem Rec] 2022 Dec; Vol. 22 (12), pp. e202200152. Date of Electronic Publication: 2022 Sep 14.Publisher: Wiley Country of Publication: United States NLM ID: 101085550 Publication Model: Print-Electronic Cited Medium:

Record details

Read Online Read More Add to Saved list

Academic Journal

A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.

Authors : Lien JC; School of Pharmacy, China Medical University, Taichung, Taiwan.; Department of Medical Research, Hospital of China Medical University, Taichung, Taiwan.

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*pharmacology ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology ; Lung Neoplasms/Lung Neoplasms/Lung Neoplasms/*drug therapy

Source: British journal of pharmacology [Br J Pharmacol] 2019 Oct; Vol. 176 (20), pp. 4034-4049. Date of Electronic Publication: 2019 Sep 15.Publisher: Wiley Country of Publication: England NLM ID: 7502536 Publication Model: Print-Electronic Cited Medium:

Record details

Read Online Read More Add to Saved list

Editorial & Opinion

bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti-angiogenic agent apatinib combination therapy.

Authors : Xu G; The First Clinical Medical College of Lanzhou University, Lanzhou, China.; Cui L

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/drug therapy ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/pathology ; Liver Neoplasms*/Liver Neoplasms*/Liver Neoplasms*/drug therapy

Source: Clinical and translational medicine [Clin Transl Med] 2022 Oct; Vol. 12 (10), pp. e1086.Publisher: Wiley Country of Publication: United States NLM ID: 101597971 Publication Model: Print Cited Medium: Internet

Record details

Read Online Read More Add to Saved list

Academic Journal

Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect.

Authors : Mulyukov Z; Novartis Pharma AG, Basel, Switzerland.; Weber S

Subjects: Visual Acuity*; Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*therapeutic use ; Ranibizumab/Ranibizumab/Ranibizumab/*therapeutic use

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2018 Oct; Vol. 7 (10), pp. 660-669. Date of Electronic Publication: 2018 Aug 15.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium:

Record details

Read Online Read More Add to Saved list